Nektar Therapeutics (NKTR) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access NKTR Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Nektar Therapeutics adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent39.27
Available-for-sale Securities, Debt Securities, Current MA0.00
Cash & Short-term Investments39.00
Other Current Assets0.00
Total loans net2.16
Total Current Assets739.40
Equipment/Property/Plant Net0.00
Long-term investments339.06
Other Assets, Noncurrent714.65
Operating Lease Right Of Use Asset-
Total Assets1,095.13
Liabilities
Accounts Payable, Current AC24.89
Accrued Liabilities, Current AC23.39
Other Liabilities, Current22.71
Total Current Liabilities70.99
Total Long-term Debt0.00
Other liabilities, Noncurrent121.02
Operating Lease Liability Current22.53
Operating Lease Liability Noncurrent60.63
Total Liabilities192.01
Stockholders' Equity
Common Stock Value0.00
Treasury Stock Value0.00
Additional Paid In Capital Common Stock4,750.69
Retained Earnings / Accumulated Deficit-3,845.81
Accumulated Other Comprehensive Income-1.76
Other Equity-1.76
Common Stockholder's Equity903.12
Total Stockholder's Equity903.12
Liabilities & Stockholder's Equity1,095.13
4 historic quarters locked

Sign in to unlock the full Nektar Therapeutics balance sheet history.

About Nektar Therapeutics Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-349805

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.